170 related articles for article (PubMed ID: 11522331)
21. Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.
Acquas E; Pisanu A; Marrocu P; Goldberg SR; Di Chiara G
Eur J Pharmacol; 2001 May; 419(2-3):155-61. PubMed ID: 11426837
[TBL] [Abstract][Full Text] [Related]
22. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.
Järbe TU; Andrzejewski ME; DiPatrizio NV
Pharmacol Biochem Behav; 2002 Nov; 73(4):911-9. PubMed ID: 12213538
[TBL] [Abstract][Full Text] [Related]
23. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
Katsidoni V; Kastellakis A; Panagis G
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
[TBL] [Abstract][Full Text] [Related]
24. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice.
Valjent E; Maldonado R
Psychopharmacology (Berl); 2000 Jan; 147(4):436-8. PubMed ID: 10672638
[TBL] [Abstract][Full Text] [Related]
25. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
Manzanares J; Corchero J; Fuentes JA
Brain Res; 1999 Aug; 839(1):173-9. PubMed ID: 10482810
[TBL] [Abstract][Full Text] [Related]
26. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
27. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
28. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.
Solinas M; Tanda G; Justinova Z; Wertheim CE; Yasar S; Piomelli D; Vadivel SK; Makriyannis A; Goldberg SR
J Pharmacol Exp Ther; 2007 Apr; 321(1):370-80. PubMed ID: 17210800
[TBL] [Abstract][Full Text] [Related]
29. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
30. Cannabimimetic properties of ajulemic acid.
Vann RE; Cook CD; Martin BR; Wiley JL
J Pharmacol Exp Ther; 2007 Feb; 320(2):678-86. PubMed ID: 17105826
[TBL] [Abstract][Full Text] [Related]
31. delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory.
Wise LE; Varvel SA; Selley DE; Wiebelhaus JM; Long KA; Middleton LS; Sim-Selley LJ; Lichtman AH
Psychopharmacology (Berl); 2011 Oct; 217(4):485-94. PubMed ID: 21559804
[TBL] [Abstract][Full Text] [Related]
32. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
Lichtman AH; Martin BR
Pharmacol Biochem Behav; 1997; 57(1-2):7-12. PubMed ID: 9164547
[TBL] [Abstract][Full Text] [Related]
33. Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.
Egashira N; Ishigami N; Mishima K; Iwasaki K; Oishi R; Fujiwara M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):499-506. PubMed ID: 18029074
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological evaluation of aerosolized cannabinoids in mice.
Lichtman AH; Peart J; Poklis JL; Bridgen DT; Razdan RK; Wilson DM; Poklis A; Meng Y; Byron PR; Martin BR
Eur J Pharmacol; 2000 Jul; 399(2-3):141-9. PubMed ID: 10884513
[TBL] [Abstract][Full Text] [Related]
35. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Järbe TU; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2006 Jan; 184(1):36-45. PubMed ID: 16307294
[TBL] [Abstract][Full Text] [Related]
36. Effects of the cannabinoid ligand SR 141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys.
Nakamura-Palacios EM; Winsauer PJ; Moerschbaecher JM
Behav Pharmacol; 2000 Aug; 11(5):377-86. PubMed ID: 11103889
[TBL] [Abstract][Full Text] [Related]
37. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
McMahon LR; France CP
Exp Clin Psychopharmacol; 2003 Nov; 11(4):286-93. PubMed ID: 14599262
[TBL] [Abstract][Full Text] [Related]
38. Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat.
Freedland CS; Whitlow CT; Miller MD; Porrino LJ
Synapse; 2002 Aug; 45(2):134-42. PubMed ID: 12112406
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of learning and memory impairment induced by delta9-tetrahydrocannabinol in rats.
Mishima K; Egashira N; Hirosawa N; Fujii M; Matsumoto Y; Iwasaki K; Fujiwara M
Jpn J Pharmacol; 2001 Dec; 87(4):297-308. PubMed ID: 11829149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
